Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral- naive HIV-infected patients. Commentary
- Author
- JEMSEK, Joseph G1 ; ARATHOON, Eduardo2 ; DUBE, Michael P9 ; ARLOTTI, Massimo3 ; PEREZ, Carlos4 ; SOSA, Nestor5 ; POKROVSKIY, Vadim6 ; THIRY, Alexandra7 ; SOCCODATO, Michael7 ; NOOR, Mustafa A8 ; GIORDANO, Michael7
[1] Jemsek Clinic, Huntersville, North Carolina, United States
[2] Hospital General San Juan de Dios, Guatemala, Guatemala City, United States
[3] Ospedale degli Infermi, Rimini, Italy
[4] Hospital Clínico de La Pontificia Universidad Católica, Santiago, Chile
[5] Consultorio Royal Center, Panama City, Panama
[6] Federal AIDS Center, Moscow, Russian Federation
[7] Bristol-Myers Squibb, Wallingford, Connecticut, United States
[8] Bristol-Myers Squibb, Princeton, New Jersey, United States
[9] Division of Infectious Diseases, Indiana University, Indianapolis, United States - Source
Clinical infectious diseases. 2006, Vol 42, Num 2, pp 273-282, 10 p ; ref : 39 ref
- Publisher
- University of Chicago Press, Chicago, IL
- Publication country
- United States
- Document type
- Article
- Language
- Russian
- Keyword (fr)
- Antirétroviral Antiviral Association médicamenteuse Atazanavir Efavirenz Lamivudine SIDA Zidovudine Traitement initial Analogue nucléoside Benzoxazine dérivé Composé acétylénique Composé non nucléoside Didésoxynucléoside Enzyme Hydrolases Immunodéficit Immunopathologie Infection Inhibiteur enzyme Inhibiteur protease Inhibiteur reverse transcriptase Nucleotidyltransferases Peptidases Pyrimidine nucléoside RNA-directed DNA polymerase Transferases Virose
- Keyword (en)
- Antiretroviral agent Antiviral Drug combination Atazanavir Efavirenz Lamivudine AIDS Zidovudine Nucleoside analog Benzoxazine derivatives Acetylenic compound Non nucleoside compound Dideoxynucleoside Enzyme Hydrolases Immune deficiency Immunopathology Infection Enzyme inhibitor Protease inhibitor Reverse transcriptase inhibitor Nucleotidyltransferases Peptidases Pyrimidine nucleoside RNA-directed DNA polymerase Transferases Viral disease
- Keyword (es)
- Antiretroviral Antiviral Asociación medicamentosa Atazanavir Efavirenz Lamivudina SIDA Zidovudina Análogo nucleósido Benzoxazina derivado Compuesto acetilénico Compuesto no nucleósido Didesoxinucleósido Enzima Hydrolases Inmunodeficiencia Inmunopatología Infección Inhibidor enzima Inhibidor proteasa Inhibitor reverse transcriptase Nucleotidyltransferases Peptidases Pirimidina nucleósido RNA-directed DNA polymerase Transferases Virosis
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02S Antibiotics. Antiinfectious agents. Antiparasitic agents / 002B02S05 Antiviral agents
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B05 Infectious diseases / 002B05C Viral diseases / 002B05C02 Human viral diseases / 002B05C02D Viral diseases of the lymphoid tissue and the blood. Aids
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B06 Immunopathology / 002B06D Immunodeficiencies. Immunoglobulinopathies / 002B06D01 Immunodeficiencies
- Discipline
- Immunopathology Infectious pathology Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 17504619
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1086/498505 
https://dx.doi.org/10.1086/498505
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:14:\"10.1086\/498505\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:190:\"Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral- naive HIV-infected patients. Commentary\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Clinical infectious diseases\";s:9:\"\u0000*\u0000stitle\";s:17:\"Clin. infect. dis\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:2:\"42\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"273\";s:8:\"\u0000*\u0000epage\";s:3:\"282\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1058-4838\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"JEMSEK\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Joseph G\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:17:\"ARATHOON, Eduardo\";i:1;s:15:\"DUBE, Michael P\";i:2;s:16:\"ARLOTTI, Massimo\";i:3;s:13:\"PEREZ, Carlos\";i:4;s:12:\"SOSA, Nestor\";i:5;s:17:\"POKROVSKIY, Vadim\";i:6;s:16:\"THIRY, Alexandra\";i:7;s:18:\"SOCCODATO, Michael\";i:8;s:15:\"NOOR, Mustafa A\";i:9;s:17:\"GIORDANO, Michael\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CIDIEL\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:190:\"Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral- naive HIV-infected patients. Commentary\";s:8:\"\u0000*\u0000place\";s:11:\"Chicago, IL\";s:6:\"\u0000*\u0000pub\";s:27:\"University of Chicago Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:14:\"10.1086\/498505\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:190:\"Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral- naive HIV-infected patients. Commentary\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Clinical infectious diseases\";s:9:\"\u0000*\u0000stitle\";s:17:\"Clin. infect. dis\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:2:\"42\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"273\";s:8:\"\u0000*\u0000epage\";s:3:\"282\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1058-4838\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"JEMSEK\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Joseph G\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:17:\"ARATHOON, Eduardo\";i:1;s:15:\"DUBE, Michael P\";i:2;s:16:\"ARLOTTI, Massimo\";i:3;s:13:\"PEREZ, Carlos\";i:4;s:12:\"SOSA, Nestor\";i:5;s:17:\"POKROVSKIY, Vadim\";i:6;s:16:\"THIRY, Alexandra\";i:7;s:18:\"SOCCODATO, Michael\";i:8;s:15:\"NOOR, Mustafa A\";i:9;s:17:\"GIORDANO, Michael\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CIDIEL\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:190:\"Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral- naive HIV-infected patients. Commentary\";s:8:\"\u0000*\u0000place\";s:11:\"Chicago, IL\";s:6:\"\u0000*\u0000pub\";s:27:\"University of Chicago Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:14:\"10.1086\/498505\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:14:\"10.1086\/498505\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:190:\"Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral- naive HIV-infected patients. Commentary\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Clinical infectious diseases\";s:9:\"\u0000*\u0000stitle\";s:17:\"Clin. infect. dis\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:2:\"42\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"273\";s:8:\"\u0000*\u0000epage\";s:3:\"282\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1058-4838\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"JEMSEK\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Joseph G\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:17:\"ARATHOON, Eduardo\";i:1;s:15:\"DUBE, Michael P\";i:2;s:16:\"ARLOTTI, Massimo\";i:3;s:13:\"PEREZ, Carlos\";i:4;s:12:\"SOSA, Nestor\";i:5;s:17:\"POKROVSKIY, Vadim\";i:6;s:16:\"THIRY, Alexandra\";i:7;s:18:\"SOCCODATO, Michael\";i:8;s:15:\"NOOR, Mustafa A\";i:9;s:17:\"GIORDANO, Michael\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CIDIEL\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:190:\"Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral- naive HIV-infected patients. Commentary\";s:8:\"\u0000*\u0000place\";s:11:\"Chicago, IL\";s:6:\"\u0000*\u0000pub\";s:27:\"University of Chicago Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:14:\"10.1086\/498505\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:190:\"Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral- naive HIV-infected patients. Commentary\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Clinical infectious diseases\";s:9:\"\u0000*\u0000stitle\";s:17:\"Clin. infect. dis\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:2:\"42\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"273\";s:8:\"\u0000*\u0000epage\";s:3:\"282\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1058-4838\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"JEMSEK\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Joseph G\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:17:\"ARATHOON, Eduardo\";i:1;s:15:\"DUBE, Michael P\";i:2;s:16:\"ARLOTTI, Massimo\";i:3;s:13:\"PEREZ, Carlos\";i:4;s:12:\"SOSA, Nestor\";i:5;s:17:\"POKROVSKIY, Vadim\";i:6;s:16:\"THIRY, Alexandra\";i:7;s:18:\"SOCCODATO, Michael\";i:8;s:15:\"NOOR, Mustafa A\";i:9;s:17:\"GIORDANO, Michael\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CIDIEL\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:190:\"Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral- naive HIV-infected patients. Commentary\";s:8:\"\u0000*\u0000place\";s:11:\"Chicago, IL\";s:6:\"\u0000*\u0000pub\";s:27:\"University of Chicago Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:14:\"10.1086\/498505\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:190:\"Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral- naive HIV-infected patients. Commentary\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Clinical infectious diseases\";s:9:\"\u0000*\u0000stitle\";s:17:\"Clin. infect. dis\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:2:\"42\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"273\";s:8:\"\u0000*\u0000epage\";s:3:\"282\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1058-4838\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"JEMSEK\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Joseph G\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:10:{i:0;s:17:\"ARATHOON, Eduardo\";i:1;s:15:\"DUBE, Michael P\";i:2;s:16:\"ARLOTTI, Massimo\";i:3;s:13:\"PEREZ, Carlos\";i:4;s:12:\"SOSA, Nestor\";i:5;s:17:\"POKROVSKIY, Vadim\";i:6;s:16:\"THIRY, Alexandra\";i:7;s:18:\"SOCCODATO, Michael\";i:8;s:15:\"NOOR, Mustafa A\";i:9;s:17:\"GIORDANO, Michael\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CIDIEL\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:190:\"Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral- naive HIV-infected patients. Commentary\";s:8:\"\u0000*\u0000place\";s:11:\"Chicago, IL\";s:6:\"\u0000*\u0000pub\";s:27:\"University of Chicago Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
